Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics

► Unwanted immunogenicity is a hurdle for the development of biotherapeutics. ► Host and/or protein factors may affect clinical anti-biotherapeutic antibody responses. ► Concerted efforts to correlate preclinical and clinical immunogenicity prediction/mitigation are needed. ► Biosimilars and biobett...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug discovery today 2012-12, Vol.17 (23-24), p.1282-1288
Hauptverfasser:	Barbosa, Maria D.F.S., Kumar, Sandeep, Loughrey, Helen, Singh, Satish K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - chemistry Antibody Formation Biological and medical sciences Biological Products - adverse effects Biological Products - chemistry Biological Products - immunology Biopharmaceutics - methods Biosimilar Pharmaceuticals - adverse effects Biosimilar Pharmaceuticals - chemistry Drug Discovery - methods General pharmacology Humans Interferon beta-1a Interferon-beta - chemistry Interferon-beta - immunology Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Proteins - adverse effects Proteins - chemistry Proteins - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!